{"id":1648,"date":"2023-06-25T17:29:04","date_gmt":"2023-06-25T17:29:04","guid":{"rendered":"https:\/\/kidneydiseaseclinic.net\/kdc\/artemether-with-lumefantrine\/"},"modified":"2023-06-25T19:59:25","modified_gmt":"2023-06-25T19:59:25","slug":"artemether-with-lumefantrine","status":"publish","type":"post","link":"https:\/\/kidneydiseaseclinic.net\/kdc\/artemether-with-lumefantrine\/","title":{"rendered":"Artemether with lumefantrine"},"content":{"rendered":"

<\/p>\n

Artemether with lumefantrine<\/h1>\n

CLINICAL USE<\/h3>\n

Treatment of malaria<\/p>\n

DOSE IN NORMAL RENAL FUNCTION<\/h3>\n

>35 kg: 6 doses of 4 tablets, i.e. 24 tablets
\ngiven over 60 hours
\nGive 4 tablets at 0, 8, 24, 36, 48 and 60 hours<\/p>\n

PHARMACOKINETICS<\/h3>\n
  • Molecular weight                           :
    \nArtemether: 298.4;
    \nlumefantrine: 528.9<\/li>\n
  • %Protein binding                           :
    \nArtemether: 95.4;
    \nlumefantrine: 99.9<\/li>\n
  • %Excreted unchanged in urine     :
    \nNo data<\/li>\n
  • Volume of distribution (L\/kg)       :
    \nArtemether: 5.4\u20138.6;
    \nlumefantrine: 3.8<\/li>\n
  • half-life \u2013 normal\/ESRD (hrs)      :
    \nArtemether 0.8\u20137;
    \nlumefantrine: 48\u201372
    \n(4\u20136 days in people
    \nwith falciparum
    \nmalaria)<\/p>\n

    DOSE IN RENAL IMPAIRMENT<\/h3>\n

    GFR (mL\/MIN)<\/h4>\n<\/li>\n
  • 20 to 50     : Dose as in normal renal function<\/li>\n
  • 10 to 20     : Dose as in normal renal function<\/li>\n
  • <10           :
    \nDose as in normal renal function.
    \nUse with caution<\/p>\n

    DOSE IN PATIENTS UNDERGOING RENAL REPLACEMENT THERAPIES<\/h3>\n<\/li>\n
  • CAPD                :
    \nUnknown dialysability. Dose as in
    \nGFR <10 mL\/min<\/li>\n
  • HD                     :
    \nUnknown dialysability. Dose as in
    \nGFR <10 mL\/min<\/li>\n
  • HDF\/high flux   :
    \nUnknown dialysability. Dose as in
    \nGFR <10 mL\/min<\/li>\n
  • CAV\/VVHD      :
    \nUnknown dialysability. Dose as in
    \nnormal renal function<\/p>\n

    IMPORTANT DRUG INTERACTIONS<\/h3>\n

    Potentially hazardous interactions with other drugs<\/li>\n

  • Anti-arrhythmics: avoid concomitant usewith amiodarone, disopyramide, flecainide
    \nand procainamide \u2013 risk of ventricular
    \narrhythmias
    \nAntibacterials: avoid concomitant use with<\/p>\n

    macrolides and quinolones.<\/li>\n

  • Antidepressants: avoid concomitant use<\/li>\n
  • Antifungals: avoid concomitant use withimidazoles and triazoles.
    \nAntimalarials: increased risk of ventricular<\/p>\n

    arrhythmias with quinine \u2013 avoid
    \nconcomitant use.<\/li>\n

  • Antipsychotics: avoid concomitant use<\/li>\n
  • Antivirals: avoid concomitant use withamprenavir, atazanavir, indinavir, lopinavir,
    \nnelfinavir, ritonavir and saquinavir;
    \npossibly increased risk of ventricular
    \narrhythmias with tipranavir \u2013 avoid
    \nconcomitant use
    \nBeta-blockers: avoid concomitant use with<\/p>\n

    metoprolol and sotalol<\/li>\n

  • Grapefruit juice: may increasebioavailability and inhibit metabolism \u2013
    \navoid concomitant use
    \nUlcer-healing drugs: avoid concomitant<\/p>\n

    use with cimetidine<\/p>\n

    ADMINISTRATION<\/h3>\n

    Reconstition<\/h4>\n

    \u2013<\/p>\n

    Route<\/h4>\n

    Oral<\/p>\n

    Rate of Administration<\/h4>\n

    \u2013<\/p>\n

    Comments<\/h4>\n

    Take with food to increase absorption<\/p>\n

    If patient vomits within 1 hour of taking<\/p>\n

    the tablet the dose should be repeated<\/p>\n

    OTHER INFORMATION<\/h4>\n<\/li>\n
  • In renal impairment monitor ECG andpotassium levels<\/li>\n
  • Undergoes extensive metabolism by theliver<\/li>\n","protected":false},"excerpt":{"rendered":"

    Artemether with lumefantrine CLINICAL USE Treatment of malaria DOSE IN<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[1],"tags":[7],"class_list":["post-1648","post","type-post","status-publish","format-standard","hentry","category-blog","tag-post-by-auto-php"],"_links":{"self":[{"href":"https:\/\/kidneydiseaseclinic.net\/kdc\/wp-json\/wp\/v2\/posts\/1648","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/kidneydiseaseclinic.net\/kdc\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/kidneydiseaseclinic.net\/kdc\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/kidneydiseaseclinic.net\/kdc\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/kidneydiseaseclinic.net\/kdc\/wp-json\/wp\/v2\/comments?post=1648"}],"version-history":[{"count":2,"href":"https:\/\/kidneydiseaseclinic.net\/kdc\/wp-json\/wp\/v2\/posts\/1648\/revisions"}],"predecessor-version":[{"id":2945,"href":"https:\/\/kidneydiseaseclinic.net\/kdc\/wp-json\/wp\/v2\/posts\/1648\/revisions\/2945"}],"wp:attachment":[{"href":"https:\/\/kidneydiseaseclinic.net\/kdc\/wp-json\/wp\/v2\/media?parent=1648"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/kidneydiseaseclinic.net\/kdc\/wp-json\/wp\/v2\/categories?post=1648"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/kidneydiseaseclinic.net\/kdc\/wp-json\/wp\/v2\/tags?post=1648"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}